Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH006 Combination in Advanced Solid Tumors
NCT07362264Phase 1Active, not recruiting
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SH006 in liver cancer and solid tumor, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 21 days, Recommended Phase 2 Dose at 21 days and 1 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
SH006
03
Conditions
liver cancersolid tumor
Beyond the preview
Go deeper on NCT07362264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362264.